Inhaled Biologics: Overcoming Challenges and Recent Advances

Area of Science:

• Pulmonary drug delivery
• Biopharmaceutical sciences
• Respiratory medicine

Background:

• Biologics are advanced therapies but often require injections due to poor oral absorption, causing patient inconvenience.
• The pulmonary route presents an alternative for biologic delivery, utilizing the lung's large surface area and vascularization.
• Challenges include drug stability, absorption, and retention influenced by lung physiology and mucociliary clearance.

Purpose of the Study:

• To review recent advances in inhaled biologic therapies (peptides and proteins).
• To highlight strategies for overcoming biopharmaceutical and physicochemical challenges in pulmonary delivery.
• To discuss the clinical potential of next-generation inhaled biologics.

Main Methods:

• Review of current research on inhalation systems for therapeutic peptides and proteins.
• Analysis of factors influencing inhaled biologic pharmacokinetics, including lung physiology and aerosol dynamics.
• Exploration of formulation, device, and excipient optimization strategies.

Main Results:

• The pulmonary route offers potential for both local and systemic delivery of biologics, bypassing first-pass metabolism.
• Effective inhaled biologic therapy requires careful consideration of drug properties, aerosol behavior, and lung environment.
• Numerous strategies are being developed to enhance stability, absorption, and retention of inhaled biologics.

Conclusions:

• Inhaled biologics represent a significant advancement, improving patient adherence and therapeutic outcomes.
• Overcoming biopharmaceutical and physicochemical barriers is crucial for successful pulmonary delivery of biologics.
• Continued research in formulation, devices, and understanding lung interactions will drive the clinical application of inhaled biologics.